Slider
Winimed 10 product pack
Deus Medical logo

WINIMED 10 (Stanozolol)

• CAS number: 10418-03-8
• Molecular Weight: 328.49 g/mol
• Formula: C21H32N2

Authenticity protected scan our product QR code

WINIMED 10 by DEUS MEDICAL®

WINIMED 10 (Stanozolol)

Winimed 10 product pack

Overview

WINIMED 10 (Stanozolol) is a derivative of dihydrotestosterone (DHT). It is used for the treatment of anemia and hereditary angioedema which causes episodes of swelling of the face, extremities, genitals, bowel wall, and throat. It is manufactured in 10mg tablets which contain stanozolol 10mg and excipients. 

Stanozolol Mechanism of Action

It is an anabolic steroid and acts on androgen receptors. Stanozolol has weak androgenic properties which makes it useful in the treatment of children. It also seems to enhance the production of the C1NH protein. Shortage of this protein is implicated in the development of hereditary angioedema. Even though it has weak androgenic properties it can still act on the kidneys to increase erythropoietin which leads to an increase in red cell production. 

WINIMED 10 (Stanozolol) Dosage

0.5mg - 10mg taken orally daily. 

Stanozolol Side effects

Hepatotoxicity, increase in weight, acne, mood variation, hirsutism, and postmenopausal bleeding.

Stanozolol Interactions

Anticoagulants, Antidiabetic drugs, insulin. 

Composition

✓ Stanozolol . . . . . . . . . . . . . . . . . . 10mg
✓ Excipients . . . . . . . . . . . . . . . . . . . . . q.s

Winimed 10 bakc of the product packaging
Authenticity protected scan our product QR code

BECOME A PARTNER

We are offering a diverse range of pharmaceutical products, which are available only from an authorized resellers. Our highly-regarded partners are comprised of industry experts who share our values and commitment. Our goal is to strengthen our network of prestigious professionals who strive to deliver great quality products.
We believe that partnerships are essential to drive change, innovation and transformation, and we are committed to ensuring the success of our collaborations.